





INTRODUCTION

Cancer, this dreaded disease that has become one of the most important causes of death worldwide, has very wide dimensions and countless hidden angles. The need to pay attention to the dimensions of this challenge and the mobilization of specialist forces and interdisciplinary fields to master and overcome this disease as much as possible becomes more prominent with the passage of time.

For the first time at the national level, efforts are being made to hold an international congress titled Cancer Genomics Congress (CGC2023). This congress has several sections, each of which covers and responds to a very important needs in understanding and combating cancer. In this congress, an attempt has been made to have a comprehensive and complete look at different aspects of cancer by inviting all scientific societies that are somehow related to research, molecular diagnosis and targeted therapy of cancer. In addition, we aim to hold the largest interdisciplinary, scientific and commercialization event of the country.

The most important goals of this congress are to present the latest achievements in the field of cancer cell biology, molecular diagnosis, targeted treatment and personalization of cancer treatment. Doctors and pharmacists are part of the audiences of the congress who will be participate in order to retrain and develop their knowledge. Retraining points are considered for these participants.

Dr. Mostafa Ghanei, President of the CGC2023:

In terms of disease burden in the country, cancer is among the first 5 causes in the category of non-communicable diseases, which has caused deaths and imposed heavy costs on patients and the country.

Therefore, it is desirable for the government to reduce costs, for the private sector to increase income, and for the people to have effective and timely treatment. When we can combine the interests of the government, the interests of the private sector and the interests of the people, we will witness serious developments.



INTRODUCTION

- Dr. Mostafa Ghanei
 (President of the CGC2023 | Secretary of the Council of Biotechnology Development)
- Dr. Sayed Javad Mowla (Co-Scientific Secretary of the CGC2023)
- Dr. Salvatore Oliviero
 (Co-Scientific Secretary of the CGC2023 | Secretary of the SIBBM)
- Dr. Mohammad Akrami
 (Head of CanaerGenomics Consortium)
- Dr. Masoud Ebrahimi
 (Executive Secretary of the CGC2023)
- Dr. Hanifeh Mirtavoosi Mahyari
 (Scientific Programs Manager of the CGC2023)
- Dr. Nazanin Khadem
 (Cultural Ambassador of the CGC2023)
- Sajad Shariat
 (Commercialization Programs Manager of the CGC2023)
- Niloofar Zarouni
 (Secretary of the Media and Communications Committee)



CONGRESS COMMUNICATION NETWORK

In order to make it easier to invite the best researchers from around the world and to create wider international connections, CGC2023 Congress closely cooperates with The **Italian Society of Biophysics and Molecular Biology (SIBBM)**. Also, the International Relations Committee of the Congress, by recruiting volunteer students and allocating each foreign country to one of the volunteers, in the first phase, identify and prepare a list of foreign potential audiences of the Congress, and in the second phase, invite these contacts to register and attend the Congress.


CONGRESS AUDIENCE AND PARTICIPANTS

- Researchers, doctors/specialists, professors and students of bioinformatics, biology, medicine, pharmacy... active in the field of cancer
- Accelerators, startups, knowledge-based companies and pharmaceutical and commercial companies active in the field of cancer
- Health insurances
- Benefactors in the field of cancer
- Health officials and policy makers

OBJECTIVES OF HOLDING THE CONGRESS

- creating an interdisciplinary interactive environment
- Presenting the latest scientific achievements in the field of molecular diagnosis, personalized medicine and targeted treatment of cancer
- Expanding theoretical and practical knowledge of participants by holding various training workshops
- Commercialization festival to develop the cancer business environment
- Identifying the ecosystem of cancer disease in the country and providing support programs for this ecosystem

A LOOK AT THE CANCER ECOSYSTEM AND CONGRESS'S SUPPORT PROGRAMS FOR THE ECOSYSTEM COMPONENTS:



Supporting accelerators, startups, knowledge-based companies and pharmaceutical companies active in the field of cancer

Development of knowledge-based business, development of entrepreneurship and job creation are among the most important priorities of holding this congress. In this regard, the call for admitting ideas and startups, via TechAzma Accelerator as the organizer of the CGC2023 Congress, has started since June 2022, and so far, two startups have been registered and supported. Moreover, the applications of several other startups are being reviewed and evaluated. Two halls from the complex of summit halls are dedicated to holding commercialization meetings, including B2B meetings. Also, in the exhibition section of the congress, it is possible to present and introduce the products of about 200 companies active in the field of cancer.

Supporting patients, doctors and clinical centers

An important part of the country's cancer ecosystem includes patients, doctors, medical centers, health insurances and Benefactors.

The support of this collection is planned in the form of a knowledge-based startup, and as a digital platform for communication management with cancer patients. The first mission of the CancerMed startup, as one of the important outputs of the CGC2023 Congress, is to create a database for quick, reliable and easy access for patients and doctors to the latest clinical information for any type of cancer. In developed countries, there are reliable databases for cancer patients as well as doctors and researchers in the field of cancer. Unfortunately, there is currently no such database in the country, and cancer patients have the least knowledge of the condition of the disease, chances of survival, new treatment methods, and the latest effective cancer drugs. Surely, this database can play an important role in the prevention and correct treatment of cancer patients.

Supporting the development of knowledge frontiers, students, graduates, researchers, and research centers

In addition to the three-day programs of the Congress, a number of practical workshops with various topics will be presented. These workshops started since Aug 2022 with the presentation of a two-day gene cloning workshop at Tarbiat Modares University, and the rest of the workshops will be presented until the congress opening time.

In terms of supporting cancer research, a joint call to support cancer genomics research projects with the joint support of the INSF and the Biotechnology Development Council has been approved, and the registration and judging of the submitting proposals will begin soon. The calls for students' novel research idea competition, support for students' theses and dissertations, support for postdoctoral fellowship and research projects will be announced soon with the support of the Biotechnology Development Council.



HOLDING PROCESS

The congress will be held in English and Farsi and in a hybrid form (in person and virtual) in a period of 3 days simultaneously in 7 main and secondary halls of the summit hall.

TIME AND VENUE

May 2023, 3-5, Tehran (Iran International Conference Center)

CANCER GENOMICS CONSORTIUM

Fortunately, with the announcement of participation and cooperation and the formation of a consortium of 23 national and international scientific societies, the ground for holding the largest scientific and commercialization event of the country has been provided. It should be noted that the possibility of joining new scientific associations to the Cancer Genomics Consortium still exists.

CONTACT TO CGC2023

Vozara Street , Tehran ,Iran, 2nd Floor, NO35,4th Unit 🖎 +98 938 880 2787

International Congress of RGENO

May 3-5, 2023 TEHRAN, IRAN



CGC2023





























RUNXYANTORIO PENBB2....
RUNXYANTORIO PENBBPELLI
MYCAN NFK B D EK/NUP214 ALK
NFKB2EGFRWC2 IDBL
35 BCJ FRWC2 IDBL
35 BCJ FRWC7 IDBL
35 BCJ FRWC7 IDBL
35 BCJ FRWC7 IDBL
36 BCJ FRWC7 IDBL
37 BCJ F

VABL FGF4 resistant
K[Judot, LMO2 NFKB2
HOM1, RHOM2 res4 (HSS)
HOM1, RHOM2 res4 (HSS)
HER2 RHOM1, RHOM2 res4 (HSS)
HER2 RHOM1, RHOM2
LYL 4 (RES4 (HSS)
HER2 RHOM1, RHOM2
HER2 RHOM1
RHOM2 RHOM1, RHOM2
HER2 RHOM1
RHOM3 (RSS)
RARA RHOM1
RHOM3 RHOM3
RHOM3 RHOM1
RHOM3 RHOM3
RHOM3 RHOM3 RHOM3 RHOM3
RHOM3 RHOM3

GLI1 RARA/PML NOTCH
SIS (aka PDGFB) NFKB2 LCK MYH11/CBFB

Myc McF2L (OST)

NFKB2/Ca1MaS1

F6F4 (KS3)

JUNATI

GNAS (GSP) HER2/neu

RUDOXI (AML.) SK

Nfkb2 SET/CAN BC DEV/NUP214

MYCN ALK AFF4/MLLT1 MYC (C-MYC) BUNXY/MT68(ETO) MYCN

MYCN ALK AFF4/MLLT1 MYC (C-MYC) BUNXY/MT68(ETO) MYCN

MYCN ALK AFF4/MLLT1 MYC (C-MYC) BUNXY/MT68(ETO) MYCN

MYCN/MT68(ETO) MYCN/MT68(RUNX1/MTG8(ETO) MYCL LMO1, LMO2 MYH11/CBFB PIM1 RUNX1/MTG8(ETO) MCF2 (DBL) MDM2 LYL1 FGF4 (KS3)

Kraspeknup214

Kraspeknup214

SET/CAN MYC (c-MYC)

CCND1 NOTCH1 (TAN1)

RELYNRG RET ALK/NRM

NOTCH1 (TAN1) MOS

NOTCH1 (TAN1) MOS

Ca1 AXL NFKB2/Ca1 TIAM1 TCF3/PBX1 NTRK1
RUNX1/MTG8(ETO) PAX-5
SET/CAN RUNX1 (AML1)
IIAM1 NRAS RAF1 TALL TALL
SCL-2 3.6

EGFR RUNX1 (AML1) GNAS (GSP) LCK TIAM1 AFF4/MLLT11

MCF2 (DBL) TSC2 MOS HRAS AFF4/MLLT11 MDM2 NFKB2/Ca1 FGF4 (KSS3) Runx
SIS (aka PODGFB)
SIS (aka PODGFB)
DEK/NUP2
NTRK1
TCE3/PBX1

AFF4/MI

Personalized Medicine

Targeted Therapy

Molecular Diagnosis



+98 938 880 2787





